CN110248650A - 用于增强突触发生和神经突发生的方法 - Google Patents

用于增强突触发生和神经突发生的方法 Download PDF

Info

Publication number
CN110248650A
CN110248650A CN201780078374.7A CN201780078374A CN110248650A CN 110248650 A CN110248650 A CN 110248650A CN 201780078374 A CN201780078374 A CN 201780078374A CN 110248650 A CN110248650 A CN 110248650A
Authority
CN
China
Prior art keywords
dspbn
pharmaceutically acceptable
blast
acceptable salt
nac
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780078374.7A
Other languages
English (en)
Chinese (zh)
Inventor
查理德·D·科普尔
李威
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hough Ear Institute
Original Assignee
Hough Ear Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hough Ear Institute filed Critical Hough Ear Institute
Publication of CN110248650A publication Critical patent/CN110248650A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/085—Angiotensins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CN201780078374.7A 2016-10-31 2017-10-27 用于增强突触发生和神经突发生的方法 Pending CN110248650A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201662415101P 2016-10-31 2016-10-31
US62/415,101 2016-10-31
US201762488740P 2017-04-22 2017-04-22
US62/488,740 2017-04-22
US201762510596P 2017-05-24 2017-05-24
US62/510,596 2017-05-24
US201762550345P 2017-08-25 2017-08-25
US62/550,345 2017-08-25
PCT/US2017/058834 WO2018081614A1 (en) 2016-10-31 2017-10-27 Methods for enhancing synaptogenesis and neuritogenesis

Publications (1)

Publication Number Publication Date
CN110248650A true CN110248650A (zh) 2019-09-17

Family

ID=62020809

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780078374.7A Pending CN110248650A (zh) 2016-10-31 2017-10-27 用于增强突触发生和神经突发生的方法

Country Status (5)

Country Link
US (2) US10576125B2 (enExample)
EP (1) EP3532042A4 (enExample)
JP (1) JP2019537582A (enExample)
CN (1) CN110248650A (enExample)
WO (1) WO2018081614A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020036656A2 (en) 2018-04-27 2020-02-20 The Regents Of The University Of California Inhibition of lipofuscin aggregation by molecular tweezers
US12076332B2 (en) 2018-04-27 2024-09-03 The Regents Of The University Of California Treatment of lysosomal storage disorders
US20210137861A1 (en) * 2018-05-03 2021-05-13 Hough Ear Institute Methods for reducing accumulated pathologic tau protein
WO2020056056A1 (en) 2018-09-12 2020-03-19 Hough Ear Institute Methods for treating hearing loss incident to cochlear implant surgery
CN113811358A (zh) * 2019-03-26 2021-12-17 通尼克斯制药控股有限公司 S-(n,n-二乙基氨基甲酰基)谷胱甘肽的盐形式
WO2020243478A1 (en) * 2019-05-29 2020-12-03 Massachusetts Eye And Ear Infirmary Fibroblast growth factor 2 (fgf2) for treatment of human sensorineural hearing loss
CN112939823A (zh) * 2019-12-10 2021-06-11 中国石油天然气股份有限公司 泥页岩抑制剂制备方法及抑制剂的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090306225A1 (en) * 2008-04-21 2009-12-10 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
WO2014014828A1 (en) * 2012-07-16 2014-01-23 Cornell University Nicotinamide riboside to treat hearing loss
WO2014195322A1 (en) * 2013-06-04 2014-12-11 Acturum Life Science AB Triazole compounds and their use as gamma secretase modulators

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5488145A (en) * 1993-12-23 1996-01-30 Oklahoma Medical Research Foundation 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps
US6064064A (en) * 1996-03-01 2000-05-16 Fire Sentry Corporation Fire detector
KR100628847B1 (ko) 1998-09-25 2006-09-29 세파론, 인코포레이티드 감각 유모 세포 및 와우 뉴런의 손상의 예방 또는 치료 방법
TR201911199T4 (tr) * 2009-03-27 2019-08-21 Moleac Pte Ltd Hücre büyümesini arttırmak için tedavi.
US10555915B2 (en) * 2009-08-24 2020-02-11 Hough Ear Institute Methods for treating acute acoustic trauma
ES2893825T3 (es) * 2011-02-04 2022-02-10 Hough Ear Inst Métodos de tratamiento de lesiones cerebrales
CA2883896C (en) * 2012-09-07 2023-03-07 Massachusetts Eye & Ear Infirmary Treating hearing loss
US20180256756A1 (en) * 2015-09-18 2018-09-13 Oklahoma Medical Research Foundation Method of transporting an agent across blood-brain, blood-cochlear or blood-cerebrospinal fluid barrier

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090306225A1 (en) * 2008-04-21 2009-12-10 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
WO2014014828A1 (en) * 2012-07-16 2014-01-23 Cornell University Nicotinamide riboside to treat hearing loss
WO2014195322A1 (en) * 2013-06-04 2014-12-11 Acturum Life Science AB Triazole compounds and their use as gamma secretase modulators

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
XIAOPING DU ET AL.: "Ameliorative Effects of Antioxidants on the Hippocampal Accumulation of Pathologic Tau in a Rat Model of Blast-Induced Traumatic Brain Injury", 《OXIDATIVE MEDICINE AND CELLULAR LONGEVITY》 *
佚名: "Otologic begins Phase I trial of NHPN-1010 to treat hearing disorders", 《HTTPSWWW.CLINICALTRIALSARENA.COMNEWSNEWSOTOLOGIC-BEGINS-PHASE-I-TRIAL-OF-HNPN-1010-TO-TREAT-HEARING-DISORDERS-4447170》 *
佚名: "SOUND MEDICINE", 《NATURE MEDICINE》 *

Also Published As

Publication number Publication date
US20180117115A1 (en) 2018-05-03
US20200164021A1 (en) 2020-05-28
JP2019537582A (ja) 2019-12-26
EP3532042A1 (en) 2019-09-04
US10576125B2 (en) 2020-03-03
WO2018081614A1 (en) 2018-05-03
EP3532042A4 (en) 2020-06-24

Similar Documents

Publication Publication Date Title
US10576125B2 (en) Methods for enhancing synaptogenesis and neuritogenesis
Sivak The aging eye: common degenerative mechanisms between the Alzheimer's brain and retinal disease
US12336974B2 (en) Methods and compositions for preventing and treating auditory dysfunctions
Kuehn et al. Retinal ganglion cell death in glaucoma: mechanisms and neuroprotective strategies.
US20220387438A1 (en) Calcineurin inhibitors of the setron family for the treatment of hearing loss
JP6099574B2 (ja) 外傷性脳損傷を処置する方法
Akaiwa et al. Topical ripasudil suppresses retinal ganglion cell death in a mouse model of normal tension glaucoma
US20230078820A1 (en) Fenfluramine for treatment of demyelinating diseases and conditions
Stallings et al. Long-term normalization of calcineurin activity in model mice rescues Pin1 and attenuates Alzheimer’s phenotypes without blocking peripheral T cell IL-2 response
Jo et al. Activation of lysosomal function ameliorates Amyloid-β-Induced tight junction disruption in the retinal pigment epithelium
US20210038589A1 (en) Uses, compositions and methods
JP2021523126A (ja) 蓄積した病理学的Ｔａｕタンパク質を低減する方法
US20250339422A1 (en) Methods for enhancing cellular clearance of pathological molecules via activation of the cellular protein ykt6
CN113855803B (zh) Prmt5抑制剂在用于制备听力保护药物中的用途
AU2019350443A1 (en) Combination of acetylcholinesterase inhibitor and 5-HT4 receptor agonist as neuroprotective agent in the treatment of neurodegenerative diseases
HK40012341A (en) Methods for enhancing synaptogenesis and neuritogenesis
Pavlova et al. Changes in the levels of neurospecific proteins and indices of apoptosis in the rat cornea at chronic ethanol consumption: protective effects of thiamine administration
Berkoz The role of oxidative stress in Alzheimer’s disease
Zhang et al. The GLP-1/GIP dual receptor agonist DA5-CH is superior to Exendin-4 in protecting neurons in the 6-OHDA rat Parkinson Model
Wu et al. Ubiquitin-specific protease 14 inhibition promotes mitophagy and attenuates neural apoptosis after spinal cord injury
AU2018100066A4 (en) Methods for Treating Cancer
TWI726172B (zh) 一種醫藥組合物用於製備治療、減少、預防或改善視神經病變後的視覺功能退化之藥物的用途
KR20170085792A (ko) Tsp-1을 포함하는 알츠하이머병 예방 또는 치료용 조성물
Forest Characterizing The Protection Of An N-Terminal Active Core Peptide Within Β-Amyloid Against Β-Amyloid Neurotoxicity
EP3820471A1 (en) Treatment of chronic traumatic encephalopathy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40012341

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190917

WD01 Invention patent application deemed withdrawn after publication